2. Metabolic Enzyme/Protease
  3. Oxidative Phosphorylation
  4. XN methyl pyrazole

XN methyl pyrazole (XP) is an orally active, blood-brain barrier permeable uncoupler/proton carrier. XN methyl pyrazole uncouples oxidative phosphorylation, depolarizes mitochondrial transmembrane potential, increases energy expenditure, spontaneous activity levels, and cortical inosine monophosphate levels. XN methyl pyrazole reduces plasma purine and energy metabolite levels, improves glucose tolerance, and decreases weight gain, while avoiding potential estrogenic side effects. XN methyl pyrazole can be used in studies related to diet-induced obesity and insulin resistance.

For research use only. We do not sell to patients.

XN methyl pyrazole

XN methyl pyrazole Chemical Structure

CAS No. : 2820169-36-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

XN methyl pyrazole Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

XN methyl pyrazole (XP) is an orally active, blood-brain barrier permeable uncoupler/proton carrier. XN methyl pyrazole uncouples oxidative phosphorylation, depolarizes mitochondrial transmembrane potential, increases energy expenditure, spontaneous activity levels, and cortical inosine monophosphate levels. XN methyl pyrazole reduces plasma purine and energy metabolite levels, improves glucose tolerance, and decreases weight gain, while avoiding potential estrogenic side effects. XN methyl pyrazole can be used in studies related to diet-induced obesity and insulin resistance[1].

In Vitro

XN methyl pyrazole (0-50 μM; 24 h) does not reduce the viability of HepG2 or C2C12 cells at concentrations below 50 μM after 24 h incubation[1].
XN methyl pyrazole (1-15 μM; 1 h) acts as a protonophore to depolarize the mitochondrial transmembrane potential in C2C12 cells at concentrations from 1 to 15 μM after 1 h incubation, uncoupling oxidative phosphorylation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

XN methyl pyrazole Related Antibodies
In Vivo

XN methyl pyrazole (30 mg/kg; p.o.; once daily; 11 weeks) improves diet-induced obesity and insulin resistance in male C57BL/6J mice by increasing energy expenditure by up to 27% and locomotor activity, while reducing weight gain and HOMA-IR by 77.9%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (9-week-old male, diet-induced obesity via 12-week high-fat diet)[1]
Dosage: 30 mg/kg
Administration: p.o.; once daily; 11 weeks
Result: Reduced final body weight to 37.87 g compared to 40.42 g in controls.
Improved glucose tolerance compared to controls.
Reduced homeostatic model assessment of insulin resistance (HOMA-IR) by 77.9% to 10.94.
Increased mean energy expenditure by 20−27% compared to controls.
Increased respiratory exchange ratio compared to controls.
Increased total movement compared to controls.
Increased locomotor movement by 75-135% compared to controls.
Increased percent ambulatory time compared to controls.
Decreased plasma concentrations of purine metabolites (adenosine monophosphate, inosine monophosphate, inosine, hypoxanthine, xanthine) and creatine relative to controls.
Increased cortical inosine monophosphate abundance by 76% compared to controls.
Caused no significant changes in plasma triglycerides, total cholesterol, inflammatory cytokines (MCP-1, IL-6), or liver enzyme (AST, ALT) activities relative to controls.
Clinical Trial
Molecular Weight

380.44

Formula

C22H24N2O4
CAS No.
SMILES

OC1=CC(OC)=C(C2=NN(C)C(C3=CC=C(O)C=C3)=C2)C(O)=C1C/C=C(C)\C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

XN methyl pyrazole Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

XN methyl pyrazole2820169-36-4XPOxidative PhosphorylationHepG2male C57BL/6J miceinosine monophosphateinsulin resistanceoxidative phosphorylationUCP1C2C12 cellsdiet-induced obesityHOMA-IRmitochondrial transmembrane potentialInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
XN methyl pyrazole
Cat. No.:
HY-139994
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.